Healthcare News Protein Expression Systems Market | Page 3

REPORT DESCRIPTION
Protein Expression Systems Market Taxonomy:
The demand for protein therapeutics has increased considerably, owing to increase in prevalence of chronic
diseases and development of plasma-derived therapies. In recent years, proteins expression systems have
gained significant traction for therapeutic applications and the number of proteins launched or approved into
clinical trials has continually increased. According to the National Center for Biotechnology Information
(NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved more than 140 recombinant
therapeutic proteins for human use and several hundred are currently in development.
However, high cost associated with therapeutic proteins and stringent government regulations towards
approval of protein therapies are expected to hinder market growth. For instance, in India, a vial of Avastin
(Bevacizumab mostly produced by the mammalian cell expression system), a monoclonal antibody, cost
between US$ 372.65 to US$ 402.46. Moreover, immunogenicity is also a major concern for all recombinant
drugs, as all biotechnologically produced therapeutics may exhibit some form of immunogenicity.
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2383
© Coherent market Insights. All Rights Reserved